drugset

drugset / Trial / NCT00300768

Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection

NCT00300768 ↗

Phase 2 Completed 172 enrolled Medicines Development for Global Health World Health Organization · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study was to determine the safety and tolerability of moxidectin in subjects infected with Onchocerca volvulus (a parasitic worm).

Timeline

Start: 2006-09-06
Primary completion: 2009-11
Completion: 2009-11-29

Publications

Results Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2953. doi: 10.1371/journal.pntd.0002953. eCollection 2014 Jun.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ivermectin	Small molecule	150 ug/kg	Oral
Subject	Moxidectin	Other / unclassified	2 mg	Oral
Subject	Moxidectin	Other / unclassified	4 mg	Oral
Subject	Moxidectin	Other / unclassified	8 mg	Oral

Indications